Category: ID Pharmacy
Pharm2Exam Table: Does methenamine prevent recurrent urinary tract infections (UTIs)?
The following is a clinical review written by Lauren Hoeft, PharmD, a recent graduate of the UNMC College of Pharmacy, and supervised by Scott Bergman PharmD FIDSA, Clinical Pharmacy Coordinator of Nebraska Medicine Antimicrobial Stewardship Program Does methenamine prevent recurrent urinary tract infections (UTIs)? Urinary tract infections (UTIs) are one of the most common indications […]
Sep 19, 2019
Pharm2Exam Table: What is persistent MRSA bacteremia and how is it treated?
The following is a clinical review written by Ashleigh Grammar, PharmD, a recent graduate of the UNMC College of Pharmacy, and supervised by Scott Bergman PharmD FIDSA, Clinical Pharmacy Coordinator of Nebraska Medicine Antimicrobial Stewardship Program (@bergmanscott) What is persistent MRSA bacteremia and how is it treated? Methicillin-resistant Staphyloccous aureus (MRSA) (photo credit: CDC Public Health Image […]
Jul 22, 2019
Pharm To Exam Table – Candida glabrata Urinary Tract Infections
The following is a clinical review written by Allison Graner, UNMC College of Pharmacy PharmD candidate 2019, and supervised by Scott Bergman PharmD FIDSA, Clinical Pharmacy Coordinator of Nebraska Medicine Antimicrobial Stewardship Program What is the appropriate treatment for urinary tract infection caused by Candida glabrata? Infections caused by the fungus known as Candida, the […]
Dec 21, 2018
Bacteriocidal versus Bacteriostatic: What Makes the Biggest Difference in VRE Bloodstream Infection?
An October 2018 publication in Critical Care Medicine by Chuang et al details a prospective study of adults in Taiwan, between 2010 -2015, aimed to assess all-cause mortality and rate of bloodstream clearance among patients with vancomycin-resistant enterococci (VRE) treated with daptomycin (bacteriocidal) versus linezolid(bacteriostatic). Patients were treated with conventional daptomycin (6 to < 9 mg/kg […]
Dec 19, 2018
Pharm to Exam Table: Doravirine DRIVES the way to more ART options
The Department of Health and Human Services HIV guidelines panel currently recommends antiretroviral therapy (ART) consisting of two nucleoside reverse transcriptase inhibitors plus an integrase inhibitor for most treatment naïve HIV infected individuals1. Prior to the advent of integrase inhibitors, the utilization of non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimens had been common. Both efavirenz […]
Oct 15, 2018
The Department of Pharmaceutical and Nutrition Care at Nebraska Medicine and the Division of Infectious Diseases at the University of Nebraska Medical Center (UNMC) are recruiting for a full-time clinical pharmacist to expand the Antimicrobial Stewardship Program and develop an Outpatient Parenteral Antimicrobial Therapy (OPAT) program in collaboration with a new Orthopedic Infectious Diseases service […]
Aug 27, 2018
Pharm To Exam Table: Dual Antiretroviral Therapy with Dolutegravir + Lamivudine
Pharm To Exam Table: Dual Antiretroviral Therapy with Dolutegravir + Lamivudine Currently, triple therapy regimens constituted with a two nucleoside reverse transcriptase inhibitor backbone and anchored by an integrase inhibitor has been the standard treatment for HIV infection. However, these conventional therapies are being challenged due to their long-term side effects. Dual therapy regimens were […]
Jun 11, 2018
Pharm to Exam Table: Monoclonal Antibodies Make Their Way into HIV Treatment
Pharm to Exam Table: Clinical Pharmacology/Antimicrobial Updates – Trogarzo® (ibalizumab-uiyk), a new monoclonal antibody treatment approved for multi-drug resistant HIV-1 On March 6th 2018, the Food and Drug Administration approved a new monoclonal antibody called ibalizumab-uiyk, marketed under the tradename Trogarzo®. Ibalizumab-uiyk (IBA) is an intravenous treatment administered every two weeks. It is intended for use […]
May 11, 2018
Pharm to Exam Table: Meet Biktarvy, the Newest of the Antiretroviral Family!
Pharm to Exam Table: Clinical Pharmacology/Antimicrobial Updates – Biktarvy, a new co-formulated integrase inhibitor-based treatment approved for HIV On February 7th 2018, the Food and Drug Administration approved a new combination antiretroviral drug called Biktarvy®(1). Biktarvy® (B/F/TAF) is a single-tablet, once daily regimen containing the novel integrase strand transfer inhibitor bictegravir coformulated with emtricitabine and tenofovir […]
Apr 2, 2018
Josh Havens, PharmD on “Why I Love ID”
Why I Love ID: Infectious diseases, in general, is quite interesting, but I can really only speak from an HIV perspective. My initial career interests were not in infectious diseases and it was not until I threw myself into this niche world of HIV that I started to recognize a true affinity toward the field. […]
Mar 23, 2018
Recent Comments